Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia

Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder

(2011) L. Elliot Hong   ARCHIVES OF GENERAL PSYCHIATRY

Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits

(2011) Manoranjan S. D’Souza et al.   NEUROPHARMACOLOGY

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

(2011) Joo-Cheol Shim et al.   NEUROPSYCHOPHARMACOLOGY

Why do patients with schizophrenia smoke?

(2010) Georg Winterer   CURRENT OPINION IN PSYCHIATRY

Meta-analysis of the acute effects of nicotine and smoking on human performance

(2010) Stephen J. Heishman et al.   PSYCHOPHARMACOLOGY

Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

(2009) Hans Rollema et al.   BIOCHEMICAL PHARMACOLOGY

Predictors of Early Abstinence in Smokers With Schizophrenia

(2009) Melissa A. Culhane et al.   JOURNAL OF CLINICAL PSYCHIATRY

Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder

(2009) Robert C. Smith et al.   SCHIZOPHRENIA RESEARCH

Varenicline Improves Mood and Cognition During Smoking Abstinence

(2008) Freda Patterson et al.   BIOLOGICAL PSYCHIATRY

Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia

(2008) Lindsay E. Jubelt et al.   PSYCHOPHARMACOLOGY